Atrium Therapeutics, Inc. Common Stock
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treat… Read more
Atrium Therapeutics, Inc. Common Stock (RNA) - Total Assets
Latest total assets as of December 2025: $1.96 Billion USD
Based on the latest financial reports, Atrium Therapeutics, Inc. Common Stock (RNA) holds total assets worth $1.96 Billion USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Atrium Therapeutics, Inc. Common Stock - Total Assets Trend (2011–2025)
This chart illustrates how Atrium Therapeutics, Inc. Common Stock’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Atrium Therapeutics, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Atrium Therapeutics, Inc. Common Stock's total assets of $1.96 Billion consist of 91.9% current assets and 8.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 19.5% |
| Accounts Receivable | $12.44 Million | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Atrium Therapeutics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Atrium Therapeutics, Inc. Common Stock's current assets represent 91.9% of total assets in 2025, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 19.5% of total assets in 2025, down from 74.4% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 3.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
Atrium Therapeutics, Inc. Common Stock Competitors by Total Assets
Key competitors of Atrium Therapeutics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Atrium Therapeutics, Inc. Common Stock - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Atrium Therapeutics, Inc. Common Stock generates 0.01x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Atrium Therapeutics, Inc. Common Stock is currently not profitable relative to its asset base.
Atrium Therapeutics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.20 | 15.73 | 17.81 |
| Quick Ratio | 9.20 | 15.73 | 17.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.60 Billion | $ 1.44 Billion | $ 294.44 Million |
Atrium Therapeutics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Atrium Therapeutics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.11 |
| Latest Market Cap to Assets Ratio | 0.11 |
| Asset Growth Rate (YoY) | 25.2% |
| Total Assets | $1.96 Billion |
| Market Capitalization | $207.28 Million USD |
Valuation Analysis
Below Book Valuation: The market values Atrium Therapeutics, Inc. Common Stock's assets below their book value (0.11 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Atrium Therapeutics, Inc. Common Stock's assets grew by 25.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Atrium Therapeutics, Inc. Common Stock (2011–2025)
The table below shows the annual total assets of Atrium Therapeutics, Inc. Common Stock from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.96 Billion | +25.20% |
| 2024-12-31 | $1.56 Billion | +148.81% |
| 2023-12-31 | $628.55 Million | -1.60% |
| 2022-12-31 | $638.80 Million | +49.40% |
| 2021-12-31 | $427.58 Million | +28.06% |
| 2020-12-31 | $333.90 Million | +244.56% |
| 2019-12-31 | $96.91 Million | +2333.63% |
| 2018-12-31 | $3.98 Million | -96.82% |
| 2013-12-31 | $125.10 Million | +100.46% |
| 2012-12-31 | $62.41 Million | +90.97% |
| 2011-12-31 | $32.68 Million | -- |